Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions
- 1 December 2012
- journal article
- review article
- Published by Harborside Press, LLC in Journal of the Advanced Practitioner in Oncology
- Vol. 3 (6) , 406-10
Abstract
Bortezomib (Velcade) is approved by the FDA for IV or SC injection in select patients with multiple myeloma or mantle cell lymphoma. The SC route functions as an alternative to IV administration for patients with poor IV access. Learn about effective strategies used to reduce injection site reactions that can occur with SC delivery.Keywords
This publication has 10 references indexed in Scilit:
- Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: A practice standard for Canadian nursesCanadian Oncology Nursing Journal, 2012
- Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myelomaHaematologica, 2012
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyThe Lancet Oncology, 2011
- Efficacy and safety of once-weekly bortezomib in multiple myeloma patientsBlood, 2010
- Factors That Influence Adherence and Strategies to Maintain Adherence to Injected Therapies for Patients With Multiple SclerosisJournal of Neuroscience Nursing, 2010
- New injection recommendations for patients with diabetesDiabetes & Metabolism, 2010
- An Update on the Treatment of Myelodysplastic SyndromesClinical Journal of Oncology Nursing, 2010
- Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendationsCurrent Medical Research and Opinion, 2010
- Performing Subcutaneous Injections: A Literature ReviewWorldviews on Evidence-Based Nursing, 2005
- Relationship Between Absorption of Radiolabeled Soluble Insulin, Subcutaneous Blood Flow, and AnthropometryDiabetes Care, 1992